BRCA and Breast Reconstruction: A Guide for High-Risk Patients

Written by Brian P. Kelley, MD, Dual Board-Certified Plastic & Hand Surgeon
Affiliate Faculty Professor, Dell Medical School at The University of Texas at Austin
Partner, Seton Ascension Institute for Reconstructive Plastic and Hand Surgery, Austin, Texas
‍Medically reviewed: June 24, 2026 · Last updated: June 24, 2026
Educational content. Not a substitute for individualized medical evaluation.

Introduction

A growing number of patients come to me already knowing they carry a genetic mutation that raises their breast cancer risk. Some have a known cancer and have just learned they are BRCA-positive. Others are healthy, learned about a family mutation through genetic testing, and are considering risk-reducing surgery to lower a risk they have not yet developed into cancer.

Both groups face reconstruction decisions that differ in important ways from the typical breast cancer patient. The timing is often different, the mastectomy is frequently bilateral, the skin and nipple are often healthy and preservable, and the planning happens with more lead time than a new cancer diagnosis usually allows.

I practice as a dual board-certified plastic and hand surgeon in Austin, Texas, an Affiliate Faculty Professor at Dell Medical School at The University of Texas at Austin, and a partner at the Seton Ascension Institute for Reconstructive Plastic and Hand Surgery. I work closely with breast surgical oncologists, genetic counselors, and oncology teams across Central Texas to plan reconstruction for patients with hereditary cancer risk. I'm also acutely aware of the impact genetic risk carries with a background in molecular biology and years spent in genetic bench research.

This guide explains how genetic risk changes reconstruction planning, what nipple-sparing mastectomy involves, the residual risk that remains after surgery, and how outcomes compare for this population.

The Genes That Raise Breast Cancer Risk

BRCA1 and BRCA2 are the best-known hereditary breast cancer genes, but they are part of a larger group. Understanding which gene is involved matters, because the level of risk and the management recommendations differ.

BRCA1 and BRCA2 are high-penetrance genes - meaning they are likely to cause issues if you carry them. Carriers have a cumulative lifetime breast cancer risk commonly cited in the range of 55% to 85% by age 70, far above the roughly 12% risk in the general female population.¹ BRCA carriers also face elevated ovarian cancer risk and a high risk of a second (contralateral) breast cancer.

PALB2 is now recognized as a high-penetrance gene with breast cancer risk approaching that of BRCA2 in many families, and risk-reducing mastectomy is a recognized option for carriers.

TP53 (Li-Fraumeni syndrome), PTEN (Cowden syndrome), CDH1 (associated with lobular breast cancer and diffuse gastric cancer), and STK11 (Peutz-Jeghers syndrome) are high-penetrance genes for which bilateral mastectomy may be an appropriate risk-reducing option.²

CHEK2, ATM, BARD1, RAD51C, and RAD51D are moderate-penetrance genes. For these, enhanced screening is often recommended, but the evidence is generally considered insufficient to recommend risk-reducing mastectomy in the absence of a strong family history or other factors.²

The decision to pursue mastectomy, and the reconstruction that follows, depends heavily on which gene is involved, the family history, and whether cancer is already present. This is a decision made with a genetic counselor and the full oncology team, not by reconstruction considerations alone.

A Special Note on TP53 and Radiation

One genetic condition deserves specific mention because it directly shapes reconstruction strategy. Patients with TP53 mutations (Li-Fraumeni syndrome) have a heightened sensitivity to radiation, which can itself induce new cancers.

For these patients, the treatment plan often aims to avoid radiation when oncologically reasonable, which can favor mastectomy over breast-conserving therapy and can favor reconstruction approaches that do not depend on a radiated field. This is one of several examples of how the specific gene changes the surgical plan, and why coordinated planning with the oncology and genetics teams matters so much.

Two Different Starting Points: Prophylactic vs. Therapeutic

Patients with a genetic mutation arrive at reconstruction from two distinct situations, and the distinction shapes everything that follows.

Prophylactic (risk-reducing) mastectomy is performed in a patient who does not have cancer but wants to reduce a high future risk. Bilateral prophylactic mastectomy reduces breast cancer risk by roughly 90% to 100% in carriers across published follow-up studies.³ Because there is no active tumor, these operations can be planned electively, the skin and nipple are usually healthy and potentially preservable, and the focus shifts toward the most natural aesthetic outcome.

Therapeutic mastectomy is performed in a patient who already has cancer and carries a mutation. Patients diagnosed with breast cancer who are found to carry a BRCA mutation often undergo mastectomy even for early-stage disease that might otherwise be eligible for lumpectomy, because the high risk of a second cancer in the same breast changes the calculus. Many also choose contralateral prophylactic mastectomy to address the unaffected side.

In practice, many genetic-risk patients have one breast treated therapeutically and the other prophylactically in the same operation. This combination is common and shapes the reconstruction plan, since the two sides may have started with different tissue quality and different oncologic constraints.

Why Reconstruction Can Be Different for Genetic-Risk Patients

Several features make reconstruction in this population distinct.

The mastectomy is usually bilateral. Reconstructing both breasts at once allows for better symmetry than reconstructing one side to match a natural breast. The reconstructive surgeon is building a matched pair rather than matching an existing breast, which often produces a more balanced result.

The skin and nipple are often healthy. In prophylactic surgery especially, there is no tumor distorting the tissue and no prior biopsy scarring in many cases. Healthy, well-perfused skin makes nipple-sparing and skin-sparing mastectomy more feasible, which improves the aesthetic starting point for reconstruction.

There is usually more time to plan. A new cancer diagnosis compresses decision-making into weeks. A known genetic risk often allows months of planning, time to consult multiple specialists, and the ability to schedule surgery around the patient's life. This lead time supports better decisions and better reconstruction planning.

Radiation is less often part of the picture. Prophylactic mastectomy patients usually do not need radiation, which removes the single biggest threat to implant reconstruction durability. My published systematic reviews documented elevated complication rates for both autologous and implant-based reconstruction in irradiated patients, with implant reconstruction failure approaching 20% in the radiation setting.^7,8 Avoiding radiation widens the reconstructive options and improves the expected longevity of implant-based results.

The patient is often younger and healthier. Genetic-risk patients frequently pursue surgery in their 30s and 40s. Younger, healthier patients tolerate longer autologous operations well and have a long horizon ahead, which factors into the choice between implant and tissue reconstruction.

Nipple-Sparing Mastectomy in the Genetic-Risk Setting

Nipple-sparing mastectomy (NSM) preserves the breast skin and the nipple-areola complex while removing the underlying breast tissue. For genetic-risk patients, especially those undergoing prophylactic surgery with healthy tissue, NSM has become a widely used and well-studied option.

The appeal is straightforward. Preserving the nipple and the full skin envelope produces a more natural reconstructed breast and higher patient satisfaction in many studies. Because prophylactic patients often have healthy, undistorted tissue, they are frequently good candidates for this approach.

The published outcomes are encouraging. A systematic review of nipple-sparing mastectomy as a risk-reducing procedure in BRCA carriers found low rates of new breast cancers, low complication rates, and high levels of satisfaction and quality of life.⁴ A large multicenter study of 787 women undergoing NSM (including 186 BRCA carriers) found that local recurrence rates were comparable between BRCA carriers and non-carriers, and that no contralateral breast cancers occurred among patients who underwent contralateral risk-reducing NSM.⁵

Patient-reported outcomes support the approach as well. A prospective study using the BREAST-Q in BRCA carriers undergoing nipple-sparing prophylactic mastectomy with immediate reconstruction documented significant improvements in self-confidence and satisfaction with breast appearance after surgery.⁶

The Residual Risk: Why "Risk-Reducing" Is Not "Risk-Eliminating"

No mastectomy removes 100% of breast tissue. Microscopic amounts of breast tissue remain on the skin flaps and, in nipple-sparing mastectomy, behind the preserved nipple-areola complex, where small ducts and lobular tissue can persist. This is why mastectomy, even prophylactic mastectomy, reduces risk by roughly 90% to 95% rather than to zero.

For nipple-sparing mastectomy specifically, the preserved nipple contains the terminal ducts of the breast, and a small amount of glandular tissue can remain. The published data are reassuring: large series of prophylactic NSM in BRCA carriers have reported very low rates of cancer developing in the preserved nipple, and the need to later remove the nipple-areola complex for a new cancer is uncommon.^4,5

Surgeons reduce this residual risk by taking a sample of tissue from behind the nipple at the time of surgery, and removing the nipple if that tissue shows concerning findings.

The takeaway for patients is straightforward. Nipple-sparing mastectomy in the genetic-risk setting is supported by good data showing low residual cancer risk and high satisfaction, but it does not reduce risk to zero, and lifelong clinical follow-up remains part of the plan. This is a reasonable and well-supported choice for many patients, made with full understanding of the small residual risk.

Implant vs. Autologous Reconstruction for Genetic-Risk Patients

Both reconstruction types are available, and the choice involves the same considerations as for any patient, with a few factors that often tilt the decision.

Implant-based reconstruction is common in this population, particularly for prophylactic patients with healthy skin and no radiation. The combination of nipple-sparing mastectomy and pre-pectoral implant placement can produce excellent results with a relatively shorter recovery. Because radiation is usually not involved in prophylactic cases, the durability concerns that affect radiated implant reconstruction are less relevant here. I discuss the implant approach in more detail in my post on pre-pectoral breast reconstruction.

Autologous (flap) reconstruction uses the patient's own tissue, most commonly a DIEP flap from the lower abdomen. It produces a soft, natural, durable result that lasts a lifetime without implant maintenance.

For younger genetic-risk patients with a long horizon ahead, the durability of autologous tissue is appealing, and the patient-reported satisfaction data favor autologous reconstruction over the long term. The trade-off is a longer operation and recovery. I cover the options for patients who are not standard DIEP candidates in my post on alternative flaps for breast reconstruction.

The right choice depends on the patient's body type, recovery tolerance, age, and preferences. Because genetic-risk patients often have time to plan and are frequently younger and healthier, they are well positioned to consider the full range of options.

Timing and Coordination With Other Risk-Reducing Surgery

Many BRCA carriers also face decisions about risk-reducing removal of the ovaries and fallopian tubes (salpingo-oophorectomy), which is generally recommended in a specific age window depending on whether the mutation is BRCA1 or BRCA2.

These surgeries are sometimes coordinated, and the sequencing is a conversation among the breast surgeon, the gynecologic oncologist, the reconstructive surgeon, and the patient. Reconstruction planning fits into a larger risk-reduction plan that addresses more than the breasts, which is one more reason the multidisciplinary team approach matters in this population.

Monitoring and Follow-Up

Genetic risk does not end with surgery, and the follow-up plan reflects that.

Before any surgery, carriers typically undergo enhanced screening, which often includes annual breast MRI in addition to mammography, beginning at an age determined by the specific gene and family history. This intensive surveillance is part of why some patients ultimately choose risk-reducing surgery.

After risk-reducing mastectomy, routine imaging surveillance of the breasts is generally not required in the same way, because the great majority of breast tissue has been removed. Clinical follow-up continues, and any new lump, skin change, or symptom is evaluated promptly given the residual tissue that remains.

Carriers also continue surveillance and risk management for the other cancers associated with their specific mutation, such as ovarian cancer for BRCA carriers. The breast reconstruction is one component of a lifelong, gene-specific care plan coordinated by the oncology and genetics teams.

Risks and Benefits

The benefits of risk-reducing mastectomy with reconstruction for high-risk patients are significant: a roughly 90% to 95% reduction in breast cancer risk, the psychological relief that many patients describe after addressing a risk that has shaped their lives, and the ability to plan reconstruction electively for the best aesthetic result.

The risks are real and deserve full discussion. Any mastectomy and reconstruction carries surgical risks including bleeding, infection, wound healing problems, and the possibility of additional operations. Nipple-sparing mastectomy adds a specific risk of reduced blood supply to the preserved nipple, which can occasionally lead to partial or complete nipple loss. Implant reconstruction carries the long-term considerations of capsular contracture and eventual maintenance surgery. Autologous reconstruction involves a longer operation, a donor site, and a small risk of flap complications.

Loss of nipple and breast sensation is common after mastectomy regardless of technique, and patients should understand that preserving the nipple does not reliably preserve its sensation. Reconstruction restores shape far better than it restores feeling.

The decision to pursue risk-reducing surgery is deeply personal. Surveillance alone is a legitimate alternative for many patients, and the choice between intensive screening and risk-reducing surgery is one that should be made with the genetics and oncology teams, weighing the individual's risk level, values, and preferences.

‍

Related Topics

• Breast reconstruction overview
• Pre-pectoral breast reconstruction
• Immediate vs. delayed breast reconstruction timing
• DIEP flap breast reconstruction
• Not a DIEP candidate? Alternative flaps for breast reconstruction
• Implant-based breast reconstruction
• Capsular contracture after implant breast reconstruction
• Breast reconstruction coverage in Texas: WHCRA and beyond
• Post-mastectomy breast sensation

‍